Recent Company News

• 08:05 AM ET Sep 18, 2025
  

  Kairos Pharma announces positive interim efficacy analysis of phase 2 trial of ENV105 ($1.68, 0.00)

• 10:58 PM ET May 21, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:26 PM ET Aug 07, 2025
  

  Santen Pharmaceutical downgraded to hold from buy at Jefferies (¥1665.0000, 0)

• 02:59 AM ET Aug 07, 2025
  

  Santen Pharmaceutical reports Q1 core net income attributable ¥7.64B vs FactSet ¥8.11B (¥1665.0000, 0)

• 09:10 PM ET May 21, 2025
  

  Santen Pharmaceutical forms medium-tern plan for FY25-29: targets Core operating profit ¥80B in FY29 (21-May post-Japan close) (¥1570.5000, +47)

• 03:02 AM ET May 13, 2025
  

  Santen Pharmaceutical to launch up-to-¥35.0B buyback, to run from 22-May through 5-Nov (¥1424.0000, 0)

• 03:00 AM ET May 13, 2025
  

  Santen Pharmaceutical reports Q4 core net income attributable ¥11.28B vs year-ago ¥8.91B (¥1424.0000, 0)

• 11:11 PM ET Apr 10, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (23 total)